duoc-01
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02254863)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adrenoleukodystrophy · Phase 1
- alpha-Mannosidosis · Phase 1
- Brain Diseases, Metabolic, Inborn · Phase 1
- Genetic Diseases, Inborn · Phase 1
- Leukodystrophy, Globoid Cell · Phase 1
- Leukodystrophy, Metachromatic · Phase 1
- Mucopolysaccharidoses · Phase 1
- Mucopolysaccharidosis II · Phase 1
- Multiple Sclerosis, Chronic Progressive · Phase 1
- Neuronal Ceroid-Lipofuscinoses · Phase 1
- Pelizaeus-Merzbacher Disease · Phase 1
- Sandhoff Disease · Phase 1
- Tay-Sachs Disease · Phase 1
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- duoc-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04943289 | Phase 1 | Nov 15, 2021 | Duke University |
| NCT02254863 | Phase 1 | Sep 1, 2014 | Duke University, The Marcus Foundation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 2 | 2 | 1 | 2014 |
| The Marcus Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1